Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 4/20 | 0.36 |
| ▸ | CNR2 | P34972 | 4/20 | 0.36 |
| ▸ | FAAH | O00519 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18301300 | 0.98 | PPARA (0.40) | PPARAALDH1A1MAPTCNR1CNR2 | |
| SCHEMBL29029661 | 0.86 | TAS1R3 (0.40) | PPARAALDH1A1CNR1FAAHKDM4E | |
| SCHEMBL32689466 | 0.84 | PPARA (0.39) | PPARAALDH1A1MAPTCNR1CNR2 | |
| SCHEMBL18301325 | 0.83 | PPARA (0.46) | PPARAALDH1A1MAPTCNR1CNR2 | |
| SCHEMBL5973606 | 0.79 | ALDH1A1 (0.53) | PPARAALDH1A1MAPTCNR1CNR2 | |
| SCHEMBL5973602 | 0.79 | ALDH1A1 (0.53) | PPARAALDH1A1MAPTCNR1CNR2 | |
| SCHEMBL26130982 | 0.78 | ALDH1A1 (0.51) | PPARAALDH1A1MAPTCNR1CNR2 | |
| SCHEMBL9398170 | 0.74 | PPARA (0.64) | PPARACNR1CNR2FAAHKDM4E | |
| SCHEMBL1877127 | 0.74 | PPARA (0.64) | PPARACNR1CNR2FAAHKDM4E | |
| SCHEMBL5188191 | 0.74 | PPARA (0.48) | PPARACNR1CNR2FAAHKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 712 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216492-A1 | USE OF ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF PEDIATRIC BRAIN CANCER | CV BIOMANUFACTURING, LLC | 2024-07-04 | — | — | US | claimed |
| EP-4329878-A1 | USE OF ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF PEDIATRIC BRAIN CANCER | Dnatrix, Inc. (US) | 2024-03-06 | — | — | EP | claimed |
| CN-114317461-A | Adenoviruses expressing immune cell stimulating receptor agonists | 德那翠丝有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-20210301264-A1 | ADENOVIRUS EXPRESSING IMMUNE CELL STIMULATORY RECEPTOR AGONIST(S) | DNATRIX, INC. (US) | 2021-09-30 | — | — | US | claimed |
| EP-3653714-A1 | ADENOVIRUS EXPRESSING IMMUNE CELL STIMULATORY RECEPTOR AGONIST(S) | DNAtrix, Inc. (US) | 2020-05-20 | — | — | EP | claimed |
| EP-3071697-B1 | ADENOVIRUS EXPRESSING IMMUNE CELL STIMULATORY RECEPTOR AGONIST(S) | DNATRIX INC (US) | 2019-10-16 | — | — | EP | claimed |
| EP-2806883-B1 | BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION | DNATRIX INC (US) | 2019-04-24 | — | — | EP | claimed |
| US-20160289645-A1 | Adenovirus Expressing Immune Cell Stimulatory Receptor Agonist(s) | DNATRIX, INC. (US) | 2016-10-06 | — | — | US | claimed |
| EP-3071697-A1 | ADENOVIRUS EXPRESSING IMMUNE CELL STIMULATORY RECEPTOR AGONIST(S) | Dnatrix Inc. (US) | 2016-09-28 | — | — | EP | claimed |
| WO-2015077624-A1 | ADENOVIRUS EXPRESSING IMMUNE CELL STIMULATORY RECEPTOR AGONIST(S) | DNATRIX, INC. (US) | 2015-05-28 | — | — | WO | claimed |
| EP-2806883-A1 | BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION | Dnatrix Inc. (US) | 2014-12-03 | — | — | EP | claimed |
| EP-2621516-A2 | INTERFERON-BETA FOR USE AS MONOTHERAPY OR IN COMBINATION WITH OTHER CANCER THERAPIES | Biogen Idec MA Inc. (US) | 2013-08-07 | — | — | EP | claimed |
| WO-2013112942-A1 | BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION | DNA TRIX, INC. (US) | 2013-08-01 | — | — | WO | claimed |
| WO-2012044684-A2 | INTERFERON-BETA FOR USE AS MONOTHERAPY OR IN COMBINATION WITH OTHER CANCER THERAPIES | BIOGEN IDEC MA INC. (US) | 2012-04-05 | — | — | WO | claimed |
| EP-2405908-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING RDEA119/BAY 869766 FOR THE TREATMENT OF SPECIFIC CANCERS | Ardea Biosciences, Inc. (US) | 2012-01-18 | — | — | EP | claimed |
| WO-2010105110-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING RDEA119/BAY 869766 FOR THE TREATMENT OF SPECIFIC CANCERS | ARDEA BIOSCIENCES, INC. (US) | 2010-09-16 | — | — | WO | claimed |
| CN-110536703-B | Combination therapy using anti-AXL antibody-drug conjugates | ADC治疗有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4396224-A1 | ANTI-DLL3 ANTIBODIES AND USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2009012268-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009012256-A1 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-01-22 | — | — | WO | disclosed |